50
Participants
Start Date
August 31, 2022
Primary Completion Date
May 9, 2025
Study Completion Date
September 30, 2025
D-4517.2
D-4517.2 (hydroxyl dendrimer VEGFR tyrosine kinase inhibitor)
Erie Retina Research, Eire
Virginia Retina Center, Leesburg
Cumberland Valley Retina Consultants, Hagerstown
West Virginia University Eye Institute, Morgantown
Midwest Eye Institute - North, Indianapolis
University Retina - Lemont, Lemont
Springield Clinic, Springfield
The Retina Institute - Clayton Office, St Louis
Texas Retina Associates - Arlington, Arlington
Strategic Clinical Research Group, Willow Park
Medical Center Ophthalmology Associates - Northwest, San Antonio
Retinal Consultants of San Antonio, San Antonio
Austin Retina Associates, Austin
Macro Trials, Los Angeles
Ophthalmic Consultants of Boston, Boston
Envision Ocular, LLC, Bloomfield
Lead Sponsor
Ashvattha Therapeutics, Inc.
INDUSTRY